DK1368041T3 - Vandigt amphotericin B-præparat - Google Patents

Vandigt amphotericin B-præparat

Info

Publication number
DK1368041T3
DK1368041T3 DK01923963T DK01923963T DK1368041T3 DK 1368041 T3 DK1368041 T3 DK 1368041T3 DK 01923963 T DK01923963 T DK 01923963T DK 01923963 T DK01923963 T DK 01923963T DK 1368041 T3 DK1368041 T3 DK 1368041T3
Authority
DK
Denmark
Prior art keywords
amphotericin
compositions
aqueous
preparation
autoclaving
Prior art date
Application number
DK01923963T
Other languages
Danish (da)
English (en)
Inventor
Srikanth Pai
Sangeeta Rivankar
Original Assignee
Bharat Serums & Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd filed Critical Bharat Serums & Vaccines Ltd
Application granted granted Critical
Publication of DK1368041T3 publication Critical patent/DK1368041T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
DK01923963T 2001-03-01 2001-03-16 Vandigt amphotericin B-præparat DK1368041T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN217MU2001 IN188924B (zh) 2001-03-01 2001-03-01
PCT/IN2001/000040 WO2002069983A1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition

Publications (1)

Publication Number Publication Date
DK1368041T3 true DK1368041T3 (da) 2005-01-17

Family

ID=11097223

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01923963T DK1368041T3 (da) 2001-03-01 2001-03-16 Vandigt amphotericin B-præparat

Country Status (23)

Country Link
US (1) US20040137049A1 (zh)
EP (1) EP1368041B1 (zh)
JP (1) JP2004523566A (zh)
KR (1) KR100810067B1 (zh)
CN (1) CN1255114C (zh)
AT (1) ATE274913T1 (zh)
AU (1) AU2001250643B2 (zh)
BG (1) BG108188A (zh)
BR (1) BR0116922A (zh)
CA (1) CA2438847A1 (zh)
CZ (1) CZ20032264A3 (zh)
DE (1) DE60105322T2 (zh)
DK (1) DK1368041T3 (zh)
EA (1) EA006241B1 (zh)
ES (1) ES2227172T3 (zh)
IN (1) IN188924B (zh)
MX (1) MXPA03007777A (zh)
NZ (1) NZ528281A (zh)
PT (1) PT1368041E (zh)
SK (1) SK10742003A3 (zh)
WO (1) WO2002069983A1 (zh)
YU (1) YU75403A (zh)
ZA (1) ZA200307307B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006069929A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc 真菌症治療製剤およびその製造方法
EA200700440A1 (ru) * 2004-09-13 2008-02-28 Бхарат Сирумс Энд Вэксинс Лтд. Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN100418536C (zh) * 2005-04-06 2008-09-17 河南省眼科研究所 一种用于眼科的抗真菌药物组合物
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
KR101629521B1 (ko) * 2010-03-16 2016-06-13 우석대학교 산학협력단 난용성 약물 가용화 및 생체막 투과증진을 위한 알코올성 수상을 내상으로 하는 리포좀, 리포좀 조성물 및 리포좀의 제조방법
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
US9744191B2 (en) 2012-03-19 2017-08-29 Yale University Antimicrobial compositions and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3222324B1 (en) 2016-03-23 2020-05-13 Wayne State University Valproate as a topical anti-fungal treatment
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
CN108344811A (zh) * 2017-01-24 2018-07-31 北京泰德制药股份有限公司 一种注射用脂质体中有机溶剂残留的检测方法
CN108309955B (zh) * 2018-04-27 2020-06-02 武昌理工学院 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

Also Published As

Publication number Publication date
EA006241B1 (ru) 2005-10-27
KR100810067B1 (ko) 2008-03-05
ATE274913T1 (de) 2004-09-15
SK10742003A3 (sk) 2004-01-08
CN1255114C (zh) 2006-05-10
YU75403A (sh) 2006-05-25
CA2438847A1 (en) 2002-09-12
DE60105322T2 (de) 2005-09-15
EA200300948A1 (ru) 2004-04-29
CN1505519A (zh) 2004-06-16
ZA200307307B (en) 2004-04-20
NZ528281A (en) 2006-11-30
IN188924B (zh) 2002-11-23
ES2227172T3 (es) 2005-04-01
AU2001250643B2 (en) 2007-03-22
BG108188A (bg) 2004-09-30
EP1368041A1 (en) 2003-12-10
DE60105322D1 (de) 2004-10-07
US20040137049A1 (en) 2004-07-15
MXPA03007777A (es) 2003-12-08
BR0116922A (pt) 2004-04-27
PT1368041E (pt) 2005-01-31
JP2004523566A (ja) 2004-08-05
KR20040018337A (ko) 2004-03-03
CZ20032264A3 (cs) 2003-12-17
WO2002069983A1 (en) 2002-09-12
EP1368041B1 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
DK1368041T3 (da) Vandigt amphotericin B-præparat
CY1120462T1 (el) Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις
WO2001092288A3 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
UA94901C2 (ru) Антибактериальные производные пиперидина
BR0112461A (pt) Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
SE0102315D0 (sv) Compounds
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
CY1110664T1 (el) Ενδορινικες συνθεσετς
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
ATE386725T1 (de) Heterocyclylverbindungen
NO20062699L (no) Smelteblandingsdispergeringer
NO20005497L (no) Heterocykliske derivater som inhiberer faktor Xa
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
WO2003090744A8 (en) Antibacterial compositions comprising metal phthalocyanine analogues
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
BRPI0519752A2 (pt) compostos peptÍdicos
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
DK1157688T3 (da) Antibakterielle vandige ophthalmiske formuleringer med ofloxacin og chitosan
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος